Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
AssigneeLixte Biotechnology, Inc.
InventorsJohn S. Kovach, Zhengping Zhuang, Jie Lu, Chunzhang Yang, Russell Lonser
Life of this patent
Estimating the term…
Abstract
A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor.
Claims26
A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor.
A method of increasing the amount of a protein encoded by an abnormal gene in a human cell carrying the abnormal gene associated with a disease characterized by a loss of protein function comprising contacting the cell with a compound which is a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor in an amount effective to increase the amount of the protein in the cell relative to such a cell not contacted with the compound.
A method of increasing the half-life of a protein encoded by an abnormal gene in a human cell carrying the abnormal gene associated with a disease characterized by a loss of protein function comprising contacting the cell with a compound which is a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor in an amount effective to increase the half-life of the protein in the cell relative to such a cell not contacted with the compound.
A method of decreasing the degradation of a protein encoded by an abnormal gene in a human cell the abnormal gene associated with a disease characterized by a loss of protein function comprising contacting the cell with a compound which is a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor in an amount effective to decrease the degradation of the protein in the cell relative to such a cell not contacted with the compound.
16-47. (canceled)
49-51. (canceled)
53-72. (canceled)
75-94. (canceled)
(canceled)
Dependencies are inferred from the claim text.